EUR 0.98
(-7.55%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | -60.56 Million USD | N/A |
2022 | -27.33 Million USD | 0.0% |
2021 | 8.41 Million USD | N/A |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | -10.99 Million USD | -40.34% |
2024 Q1 | -7.77 Million USD | 22.61% |
2023 Q3 | -11.29 Million USD | 66.16% |
2023 Q4 | -11.78 Million USD | -4.37% |
2023 Q2 | -33.37 Million USD | -490.46% |
2023 Q1 | -5.65 Million USD | 0.0% |
2022 Q3 | -1.03 Million USD | -11.54% |
2022 FY | - USD | 0.0% |
2022 Q2 | -927 Thousand USD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
BioNTech SE | 1.08 Billion EUR | 105.568% |
CureVac N.V. | -234.09 Million EUR | 74.128% |
Biotest Aktiengesellschaft | 179 Million EUR | 133.834% |
Biotest Aktiengesellschaft | 179 Million EUR | 133.834% |
BRAIN Biotech AG | -2.38 Million EUR | -2437.202% |
Formycon AG | 81.05 Million EUR | 174.72% |
Heidelberg Pharma AG | -18.7 Million EUR | -223.756% |
Medigene AG | -14.58 Million EUR | -315.242% |